Echo is developing the system as a wireless, non-invasive,transdermal continuous glucose monitoring (tCGM) system and thePrelude SkinPrep System for transdermal drug delivery.D. No sideeffects were reported in the study from the Symphony tCGM biosensoror the Prelude skin permeation. Written by Grace Rattue Copyright: Medical News China blow mould Manufacturers Today Not to be reproduced without permission of Medical News Today Additional References Citations.4% of the readings were clinicallyaccurate.Positive results were announced by Echo Therapeutics from itsclinical investigation of its Symphony tCGM System in individualswith type 1 and type 2 diabetes .
Although the actual clinical decision might differ, benign errorsresult in the same clinical outcome as accurate readings.6%. We have now shown that Symphony represents anovel approach for the tracking and trending of glucose in patientswith diabetes and holds great potential to make a meaningful impactin the management of this growing disease. The Continuous Glucose-Error Grid analysis (CG-EGA) and MeanAbsolute Relative Difference (MARD) were the primary statisticalanalysis tools the team used in order to analyze the performance ofSymphony. Importantly, a recent, major U. Results from the Investigation When the researchers compared the more than 2,600 Symphony tCGMglucose readings with reference blood glucose measurements, CG-EGArevealed that 2. Theperformance of CGM is measured as the sum of benign errors andaccurate readings. Mooney, M.5% of the readings were benign errors with acombined A+B of 96. Results from the investigation verified that the systemsuccessfully monitors the wide variety of blood sugar valuesobserved in individuals suffering with diabetes. We are extremely pleased with the outcome of the study and lookforward to the continued success of our Symphony tCGM program,including the upcoming trial in critical care patients.
Analytical Methods The researchers compared the Symphony tCGM System with referencemeasurements from a YSI 2300 STAT Plus Glucose Analyzer. Participants as well as study personnel were blinded toinvestigation data. I am a professional writer from Wiring Accessories, which contains a great deal of information about used hobart mixer , rubber molding press, welcome to visit!. In addition, Echorevealed its plan to carry out an investigation in individuals incritical care in the near future. The researchers analyzed theperformance of the Symphony tCGM System in an outpatient setting ata clinical research organization. The teamthen paired those reference measurements with the Symphony resultsvia a data analysis algorithm.S, study demonstrated thatreal-time, continuous glucose monitoring gives people with type 2diabetes, in addition to those with type 1 diabetes, improved bloodglucose control.9%, while 94. At the conclusion of the 24-hour investigationperiod, the researchers inspected the test skin sites for rednessor other undesirable effects." Study Design 20 adult patients with type 1 or type 2 diabetes were enrolled toparticipate in the investigation.
Chairman and CEO of Echo Therapeutics,explained: "This study represents another major step in our Symphonydevelopment program. Values forblood sugar measurements varied from 38 to 399 mg/dL. The CG-EGA is a categorization of all data pairs based onthe clinical significance of the accuracy. The team prepared each participant's skin using Prelude and thenapplied Symphony tCGM biosensor to the skin site. The researchers used MARD, an error calculationtool used to measure the absolute value of the average relativedifference between Symphony and the reference measurements, inorder to measure Numerical accuracy on a percentage basis.
The MARD for the investigation was 12. Patrick T. For 24 hours theteam took venous reference blood samples from intravenous line at15-minute intervals, which were then measured on a YSI 2300 STATPlus Glucose Analyzer. Accurate readings resultin the same clinical decision when based on the CGM value versusthe blood sugar value